New Drug Code accelerates hundreds of billions of Chinese medicine tablets market shuffle standards more stringent

Medical Network July 15 - July 2, the 2020 edition of the Chinese People's Republic of China Pharmacopoeia, the State Drug Administration in conjunction with the National Health and Health Commission, approved and promulgated, effective from December 30, 2020it is understood that the new version of the Pharmacopoeia for the Chinese medicine tablet industry put forward new requirements, chinese medicine growers, Chinese medicine raw materialcollection enterprises, Chinese medicine processing and circulation enterprises and other links have put forward strict management requirements to ensure the quality of Chinese medicine tabletscoupled with february this year, China has carried out a number of Chinese medicine tablets special rectification, Chinese medicine tablets hundreds of billions of markets face a reshuffleChinese medicine drink tablets are still "unqualified" heavy-hit areas of Chinese medicine drink tablets refer to under the guidance of the theory of Chinese medicine, according to the dialectical treatment and adjustment, preparation needs, the Special processing of Chinese medicine for the production of manufactured productsChinese medicine tablets can be taken directly as pharmaceutical formulations or directly, or further processed into Chinese medicine productsAccording to the national survey of Chinese herbal medicine resources, China's existing types of Chinese herbal medicine resources as many as 12,000 kindsthe problem of non-conformity of Chinese medicine tablets has long been the "sickness" of the Chinese medicine industryrecently, Hubei, Shandong, Gansu, Heilongjiang and other places have issued a series of drug quality bulletins, Chinese medicine tablets are still non-conforming batch still frequently appearOn July 9,, Gansu Provincial Drug Administration announced the announcement of drug sampling, by The Lanzhou City Food and Drug Inspection Institute and other inspection and testing institutions, marked as Ningxia Mingde Chinese medicine tablets, Sichuan Gukang Pharmaceuticals and other 7 enterprises produced 10 batches of drugs do not meet the requirements, including organic chlorine residues, sulfur dioxide residues, total ash, content is not qualifiedOn July 6,, the Hubei Provincial Drug Administration issued the 2nd issue of the drug quality announcement for 2020in this drug quality sampling, found that 65 batches did not meet the standard requirements, including 4 preparations and raw materials, 61 kinds of Chinese herbal medicine (drink tablets)On July 8,, Shandong Provincial Drug Administration issued the 4th issue of the 2020 drug quality sampling noticenotice shows that 15 production enterprises (preparation units) of 14 varieties of a total of 16 batches of drugs, sampling does not meet the standard requirements, non-conforming drug specifications for Chinese medicine tablets, there are 10 batches June, Heilongjiang Provincial Drug Administration issued the Heilongjiang Provincial Drug Administration notice on drug quality sampling (No 1 of 2020) said that after some drug production, business enterprises and user units conducted a sampling, found that 16 batches of drugs did not meet the requirements, there are 13 batches of Chinese medicine tablets (Chinese herbal medicine) for the reason that the quality of drinking tablets is not high, an industry insider admitted that Chinese medicine tablets from the processing of Chinese medicine, closer to agricultural and sideline products but at present, the production and manufacture of Chinese medicine tablets in all aspects of the concentration is low, is still small, scattered, disorder-based , the above-mentioned people believe that the lack of relevant standards is also the main reason for the difficulty of improving the quality of drinking tablets it is understood that China is still lack ingested Chinese medicine tablets and perfect drinking tablet standards , due to the lack of unified management and technical guidance, the quality of Chinese herbal medicines is uneven more to start the special rectification of Chinese medicine tablets in February this year, the State Drug Administration issued a special "Chinese medicine tablets special rectification work programme" to carry out a special inspection of Chinese medicine tablets nationwide On May 12, , the State Drug Administration held a teleconference, calling on drug regulatory authorities at all levels to implement the responsibility of territorial supervision in accordance with the "four most stringent" requirements, carefully check the production and operation of Chinese medicine tablets and preparations, resolutely investigate and punish illegal violations; On July 6, , the Fujian Provincial Drug Administration made public the notice issued before the issuance of special rectification work work on Chinese medicine tablets, pointed out that, in order to effectively implement the new revised drug management law, further strengthen the quality supervision of Chinese medicine tablets, continuously improve the quality of Chinese medicine tablets, crack down on illegal and illegal activities, regulate the production, operation and use of Chinese medicine tablets, in accordance with the unified deployment of the State Drug Administration, decided to carry out a year and a half of special rectification of Chinese medicine tablets in Fujian Province this time will increase the intensity of Chinese medicine drink tablet sampling, determine the key areas, key varieties, increase the frequency of sampling, improve the targeted sampling inspection includes illegal channels to buy Chinese medicine tablets, the use of unqualified Chinese medicine, Chinese medicine drink tablets and so on In April , Beijing issued the "Beijing Chinese medicine drink tablets special rectification program" (referred to as "programme"), officially for a year and a half of Chinese medicine tablets for a year and a half of rectification, strict inspection of the use of doping to make false, dyeing weight gain, mold deterioration and other unqualified Chinese medicine and illegal channels to buy medicines Illegal acts, as well as counterfeit ingenuity, adulteration, illegal dyeing, illegal weight gain, sulfur fumigation excessive, mold, insect decay and other issues, will be targeted at Chinese medicine drink tablets illegal acts, research and develop a "qualifying blacklist" system, linked to credit, the implementation of joint punishment reporters understand that, as of now, Fujian, Jiangsu, Shandong, Beijing, Hunan, Guizhou, Hainan, Jiangxi, Hubei, Anhui, Jiangsu and other provinces and cities have introduced a special work programme for chinese medicine tablets, into the centralized inspection stage hundred billion market to be restructured is worth noting that the newly promulgated 2020 edition of the Chinese Pharmacopoeia also imposed stricter restrictions on Chinese medicine tablets this edition of the Pharmacopoeia has focused on revising and improving the standards of Chinese medicine tablets, and revised the quality standards of more than 250 drink tablets to ensure the quality of drink tablets and clinical use perfected the "guidelines for the development of harmful residues of Chinese medicine", formulated 33 kinds of banned pesticide control requirements, stipulated that "unless otherwise provided, medicinal herbs and drinking tablets (plants) banned pesticides shall not be detected (not over quantitative limits), " and income "pharmaceutical and drink tablets inspection general rules" (general principle 0212) has formulated limits for heavy metals and harmful elements of Chinese herbal medicines and tablets (plants), and included "guidelines for the development of limits on harmful residues of Chinese medicine" as a guiding requirement Chen Qiguang, a researcher at the Institute of Economic Research of the Chinese Academy of Social Sciences in , said that with the release of the 2020 edition of the Chinese Pharmacopoeia, China will substantially raise the standards for the inspection of heavy metals in Chinese medicine, which will have a great impact on the pharmaceutical industry, especially the Chinese medicine industry family-style workshop production will be greatly reduced, industrialization of large-scale production or the main way to grow Chinese medicine in the future data show that by the end of 2017, China's Chinese medicine tablet production and processing enterprises have reached 1262, but sales of less than 100 million enterprises accounted for 70%, the overall concentration of the market is low at the same time, due to the production technology and norms are not perfect, the quality of employees weak and other factors, the quality of Chinese herbs and drink ingress still have some problems the former State Food and Drug Administration data show that in 2018 alone, the country recovered a total of 224 GMP (drug production quality management norms) certificates, of which, the Chinese medicine drink tablet industry recovered 96, accounting for a total of 43%, the Chinese medicine drink tablet industry scale, standardized production has been inevitable the report of CIC Industrial Research Institute shows that at present, the market capacity of the Chinese medicine drink tablet industry is increasing, in 2019 China's Chinese medicine drink tablet processing market sales revenue of more than 270 billion yuan, is expected to 2020 Chinese medicine tablet market demand will exceed 350 billion yuan , therefore, some industry insiders pointed out that with the development of standards, the quality of Chinese medicine continues to improve, coupled with policy, China's Chinese medicine industry will meet the rapid development period he said that in order to really improve the quality of Chinese herbal medicine, we need to pull from the demand side, so that Chinese medicine practitioners' income and efficacy linked, so that Chinese medicine practitioners pay attention to and decide the quality and source of their own use of medicinal materials, the formation of industrial chain linkage, this is a long-term solution (Reporting by Liang Wei in Beijing)